Yasuaki Ikemi
About
Yasuaki Ikemi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Yasuaki Ikemi has authored 21 papers receiving a total of 559 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Yasuaki Ikemi's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Yasuaki Ikemi is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Yasuaki Ikemi collaborates with scholars based in Japan and United States. Yasuaki Ikemi's co-authors include Young Hak Kim, Michiaki Mishima, Masahide Fukudo, Yosuke Togashi, Katsuhiro Masago, Toshiya Katsura, Yuichi Sakamori, Satohiro Masuda, Hiroki Nagai and Tomoyuki Mizuno and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Pharmaceutical Research.
In The Last Decade
Yasuaki Ikemi
20 papers receiving 542 citations
Peers
Yasuaki Ikemi
James Martin United States
Clare Weiler United States
Jeannine D. Rinderknecht Switzerland
Larry L. Schenken United States
Stefanie D. Krens Netherlands
Geetika Srivastava United States
G. Krajnik Austria
Thangam Arumugham United States
Eve A. Olman United States
Masao Sekiya Japan
Citations per year, relative to Yasuaki Ikemi Yasuaki Ikemi (= 1×)
peers
James Martin
Countries citing papers authored by Yasuaki Ikemi
Since
Specialization
Citations
This map shows the geographic impact of Yasuaki Ikemi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasuaki Ikemi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasuaki Ikemi more than expected).
Fields of papers citing papers by Yasuaki Ikemi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yasuaki Ikemi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasuaki Ikemi. The network helps show where Yasuaki Ikemi may publish in the future.
Co-authorship network of co-authors of Yasuaki Ikemi
This figure shows the co-authorship network connecting the top 25 collaborators of Yasuaki Ikemi. A scholar is included among the top collaborators of Yasuaki Ikemi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasuaki Ikemi. Yasuaki Ikemi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Masuda, Takashi, Takahiro Horimatsu, Daiki Hira, et al.. (2025). Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study. Cancer Chemotherapy and Pharmacology. 95(1). 46–46.
2.
Yonezawa, Atsushi, Daiki Hira, Tomohiro Handa, et al.. (2024). Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study. Journal of Pharmaceutical Health Care and Sciences. 10(1). 52–52.
3.
Masuda, Takashi, Takahiro Horimatsu, Shinya Yamamoto, et al.. (2024). Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series. Cancer Chemotherapy and Pharmacology. 94(4). 615–622.
4.
Imai, Satoshi, Hiroki Endo, Keita Ueda, et al.. (2022). Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder. Clinical Neuropharmacology. 45(3). 52–60.
5.
Yonezawa, Atsushi, Yuki Otani, Toshiyuki Kitano, et al.. (2019). Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkin’s Lymphoma. Pharmaceutical Research. 36(6). 82–82.
6.
Tsuda, Masahiro, Yuki Otani, Atsushi Yonezawa, et al.. (2018). Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS. Biological and Pharmaceutical Bulletin. 41(11). 1716–1721.
7.
Otani, Yuki, Atsushi Yonezawa, Masahiro Tsuda, et al.. (2017). Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats. PLoS ONE. 12(1). e0169588–e0169588.
8.
Shinke, Haruka, Satohiro Masuda, Yasuaki Ikemi, et al.. (2015). Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemotherapy and Pharmacology. 76(5). 989–996.
9.
Fukudo, Masahide, Yasuaki Ikemi, Yosuke Togashi, et al.. (2013). Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer. Clinical Pharmacokinetics. 52(7). 593–609.
10.
Takada, Tetsuya, Yasuaki Ikemi, Masahide Fukudo, et al.. (2013). Evaluation of Simple Suspension Method for Erlotinib Dosing and Its Pharmacokinetic Profile in Patients with Non-Small Cell Lung Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 39(9). 565–570.
11.
Togashi, Yosuke, Katsuhiro Masago, Satohiro Masuda, et al.. (2012). Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 70(3). 399–405.
12.
Togashi, Yosuke, Katsuhiro Masago, Masahide Fukudo, et al.. (2011). Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemotherapy and Pharmacology. 68(4). 1089–1092.
13.
Fukudo, Masahide, Yasuaki Ikemi, Yosuke Togashi, et al.. (2011). Population pharmacokinetics and pharmacogenomics of erlotinib: Effect of drug exposure on treatment outcomes in Japanese patients with non-small cell lung cancer.. Journal of Clinical Oncology. 29(15_suppl). 2549–2549.
14.
Togashi, Yosuke, Katsuhiro Masago, Masahide Fukudo, et al.. (2010). Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis. Journal of Thoracic Oncology. 5(5). 601–605.
15.
Ikemi, Yasuaki, et al.. (1991). ChemInform Abstract: Addition Reactions of 3a,6a‐Diazapentalenes with Electron Deficient Dipolarophiles.. ChemInform. 22(7).
16.
HASHIMOTO, S., et al.. (1986). ChemInform Abstract: The High Pressure Mediated Reaction of π‐Excessive Heterocycles with Maleic Anhydride Derivatives: A Synthetic Approach to Cantharidin Analogues.. Chemischer Informationsdienst. 17(47).
17.
Ikemi, Yasuaki, et al.. (1983). ChemInform Abstract: 1,3‐DIPOLAR CYCLOADDITION OF PYRIDINIUM AND DIAZINIUM DICYANOMETHYLIDES WITH BIS(TRIMETHYLSILYL)ACETYLENE: SYNTHESIS OF TRIMETHYLSILYL SUBSTITUTED INDOLIZINES AND BIS(TRIMETHYLSILYL)ACETYLENE AS AN ACETYLENE EQUIVALENT IN 1,3‐DIPOLAR CYCLOADDITION. Chemischer Informationsdienst. 14(45).
18.
Karlson, Alfred G. & Yasuaki Ikemi. (1954). COMPARISON OF THE VIRULENCE FOR MICE AND GUINEA PIGS OF AN ISONIAZID-SENSITIVE TUBERCLE BACILLUS AND ITS ISONIAZID-RESISTANT VARIANT. Mayo Clinic Proceedings. 29(4). 119–124.
19.
Ikemi, Yasuaki, et al.. (1952). EFFECT OF ISONICOTINIC ACID HYDRAZIDE (ISONIAZID) ON SURVIVAL TIME OF MICE INFECTED WITH TUBERCLE BACILLI RESISTANT TO THE DRUG IN VITRO. Mayo Clinic Proceedings. 27(19). 373–376.
20.
Karlson, Alfred G. & Yasuaki Ikemi. (1952). THE OCCURRENCE OF HUMAN-TYPE TUBERCLE BACILLI (H37Rv) RESISTANT TO ISONICOTINIC ACID HYDRAZIDE IN A CULTURE NOT PREVIOUSLY EXPOSED TO THE DRUG. Mayo Clinic Proceedings. 27(12). 239–240.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by James Martin Breakdown of academic impact, for papers by Clare Weiler Breakdown of academic impact, for papers by Jeannine D. Rinderknecht Breakdown of academic impact, for papers by Larry L. Schenken Breakdown of academic impact, for papers by Stefanie D. Krens Breakdown of academic impact, for papers by Geetika Srivastava Breakdown of academic impact, for papers by G. Krajnik Breakdown of academic impact, for papers by Thangam Arumugham Breakdown of academic impact, for papers by Eve A. Olman Breakdown of academic impact, for papers by Masao Sekiya